CPT code 79101 – IV radiopharmaceutical therapy

Key takeaways

CPT Code 79101 covers intravenous radiopharmaceutical therapy only. Oral, intracavitary, intra-arterial and intra-articular routes each have their own codes.

The radiopharmaceutical drug is never bundled into 79101, so the matching HCPCS Level II drug code goes on its own claim line.

CIGNA (through Evicore), Anthem (through Carelon) and BCBS Texas commonly require prior authorization for 79101, so verify each payer’s current code list before the infusion.

Pabau’s claims management software submits 79101 claims through Claim.MD, runs eligibility checks and tracks ERA remittances.

CPT Code 79101: definition and clinical scope

CPT Code 79101 is the American Medical Association’s procedure code for radiopharmaceutical therapy by intravenous administration. Specifically, it sits in the Nuclear Medicine subsection (78000-79999) of the Radiology chapter, among the Radiopharmaceutical Therapy codes (79005-79999).

The code covers the administration itself: the supervising physician’s work preparing, monitoring and documenting the IV infusion of the therapeutic agent. However, it does not cover diagnostic imaging, radioactive waste handling or the cost of the radiopharmaceutical.

What CPT 79101 covers and what it excludes

In fact, intravenous administration is the only route this code covers. The CPT code set assigns a separate code to each other route. As a result, picking the wrong one is a common technical denial in nuclear medicine billing.

The radiopharmaceutical’s cost is always excluded from CPT 79101 reimbursement. Therefore, bill the matching HCPCS Level II drug code on its own line of the same claim to recover the drug cost. Indeed, leaving that companion line off is another common denial trigger, alongside missing prior authorization.

HCPCS radiopharmaceutical codes reported with CPT 79101

Each therapeutic radiopharmaceutical has its own code in the HCPCS Level II codes set. In addition, that code and CPT Code 79101 go on the same claim, on separate lines. Specifically, the HCPCS line captures the drug cost, and the CPT line captures the administration service. The grid below pairs each agent with both lines, including the one agent whose administration code is not 79101.

CMS updates radiopharmaceutical HCPCS codes every year, so check the current-year file before billing a newer FDA-approved agent. However, Zevalin is the exception to the pairing above. Specifically, its drug line is A9543, but its IV administration is billed with 79403 rather than 79101. The A9607 reference covers Pluvicto’s drug line in more detail.

How to document CPT 79101 correctly

Documentation for CPT Code 79101 must establish three points clearly: the radiopharmaceutical administered, the IV route, and the supervising physician’s identity. Indeed, pre-payment reviewers check for each of them.

First, use this workflow for every CPT 79101 encounter, and confirm each payer’s clean claim submission requirements before the appointment date.

1. Referring order: Document the oncologist’s or specialist’s written order specifying the agent, dose and indication. In addition, the order must predate the infusion date.
2. Agent and dose: First, record the exact radiopharmaceutical name, lot number, dose in millicuries (mCi) or megabecquerels (MBq), and the time of administration.
3. Route confirmation: The note must state intravenous administration explicitly. Otherwise, a note that says “administered” without a route gives the payer grounds to deny for code mismatch.
4. Supervising physician: Specifically, identify the qualified nuclear medicine physician or radiation oncologist who supervised the procedure, with their NPI.
5. Radiation safety measures: Finally, document dosimetry data, the radiation safety instructions given to the patient, and the post-treatment monitoring plan under NRC or Agreement State rules.
6. Eligibility evidence: For Lu-177 PSMA therapy, include the PSMA-PET imaging result that confirms eligibility, because payer policies ask for it.

A missing element rarely triggers a denial at submission. Instead, it surfaces on audit or appeal, where a note written after the fact carries little weight.

CPT 79101 reimbursement: Medicare and commercial payer rates

Medicare pays CPT Code 79101 under the CMS Physician Fee Schedule (MPFS), with separate facility and non-facility rates. However, CMS pays for the radiopharmaceutical drug through a separate drug payment pathway, not through the 79101 rate itself.

Therefore, before submitting, confirm the place-of-service code matches where the infusion happened and that the HCPCS drug code sits on its own claim line. Indeed, the MPFS rate for 79101 changes every year, so check the current-year fee schedule rather than carrying last year’s figure forward.

In contrast, commercial payers pay negotiated rates, so check your payer-specific fee schedule or EOB history for the contracted amount. Then reconcile each electronic remittance against that rate. Otherwise, a short payment on a high-cost drug line can otherwise age into a write-off.

Prior authorization requirements for CPT 79101

Major commercial payers and Medicare Advantage plans commonly require prior authorization for CPT Code 79101 before the infusion date. Therefore, verify each payer’s current code list as part of your prior authorization process. In fact, administering without an approved authorization leads to a denial, and appeals rarely succeed when none existed.

Payer PA policies change. For this reason, check the payer’s live policy document before each treatment cycle, not only at the initial authorization.

When submitting a PA request, most payers require:

• First, the patient’s ICD-10 diagnosis code and staging information
• The specific radiopharmaceutical agent name and planned HCPCS code
• In addition, clinical notes from the referring oncologist or specialist establishing medical necessity
• Prior treatment history (for PSMA-targeted agents, prior imaging results are typically required)
• Finally, the planned infusion date and treating facility NPI

For example, for Xofigo and Pluvicto, the primary diagnosis is prostate cancer, reported with C61, plus a secondary code for the metastatic site.

Common denial reasons for CPT 79101 claims

Overall, CPT Code 79101 claims attract scrutiny because they combine a high-cost drug, frequent prior authorization requirements, and documentation that spans clinical and billing teams.

Common denial triggers include the wrong route-of-administration code, a missing HCPCS drug line, and a missing or lapsed authorization. As a result, structured denial management workflows catch these patterns before they repeat. The table pairs each trigger with its fix.

Specifically, route errors do the most damage when the note correctly describes IV administration while the claim lists 79005 (oral). Pre-payment review flags that mismatch between record and code. Therefore, coding from the route documented in the note, rather than from a standing order template, prevents this error.

CPT 79101 vs. related nuclear medicine codes

The 79005-79999 family covers the full range of therapeutic radiopharmaceutical services. In most cases, route of administration separates these codes, rather than the agent. However, the exception is 79403, which covers IV infusion of a radiolabeled monoclonal antibody such as Zevalin. For this reason, check the AAPC CPT code lookup and AMA coding resources for current descriptor language before you select a code.

How Pabau supports clean CPT 79101 claim submission

Nuclear medicine teams billing CPT Code 79101 handle high-value claims, where one denied treatment cycle can cost tens of thousands of dollars. Consequently, routing them through a medical claims clearinghouse catches formatting and payer-ID errors before the payer sees them.

Pabau’s claims management software submits claims through Claim.MD, its US clearinghouse partner, which connects to thousands of US payers. In addition, the integration covers CMS-1500 and 837P claim submission, real-time eligibility checks with supported payers, and ERA/835 remittance tracking.

For 79101, that means your team can check coverage before the infusion date and see each payment or denial as the remittance arrives. Meanwhile, your billers still own code selection and authorization, while submission and follow-up sit in the same system as the patient record.

Submit and track CPT 79101 claims in one place

Pabau’s claims management software submits CPT 79101 claims through Claim.MD, runs eligibility checks and tracks ERA remittances. Your team sees payment status without chasing payers.

Book a demo

Conclusion

CPT Code 79101 rewards preparation more than coding knowledge. Most billers know the code covers IV administration only. Instead, denials come from the handoffs. For example, an order never names the route, a drug line is left off the claim, or an authorization lapses between cycles.

Therefore, assign an owner to each of those three checks before the infusion is scheduled, and the claim leaves clean. Otherwise, a single treatment cycle can sit in appeal for weeks.

Book a demo to see how Pabau submits radiopharmaceutical claims and tracks each remittance through to payment.

Continue your research

Need to understand how clearinghouse claim edits work? Claim.MD clearinghouse overview explains how electronic claim validation catches errors before payer submission.

Tracking down the right denial codes on a 79101 rejection? Denial codes in medical billing maps CARC and RARC codes to corrective actions.

Want to understand how ERA remittance works after a 79101 claim pays? Electronic remittance advice (ERA) covers 835 transaction processing and payment reconciliation.

Preparing a prior authorization request for a radiopharmaceutical? Medical prior authorization form gives you a ready template for the clinical details payers ask for.

Billing Lutathera alongside 79101? HCPCS code A9513 covers the lutetium Lu 177 dotatate drug line and its per-millicurie units.

Frequently asked questions